Document Detail


Phase II study of nimustine hydrochloride (ACNU) plus paclitaxel for refractory small cell lung cancer.
MedLine Citation:
PMID:  19342118     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
PURPOSE: Bi-weekly administrations of nimustine hydrochloride (ACNU) plus paclitaxel were evaluated in this phase II study in patients with refractory small cell lung cancer (SCLC). METHODS: Patients who had disease progression within 3 months after treatment with irinotecan (CPT-11)-containing regimens were entered. They were treated with every other week administrations of ACNU 50 mg/m(2) plus paclitaxel 110 mg/m(2) on day 1 over 2 weeks. RESULTS: Twenty-four patients (20 males and 4 females, median age of 64 years, 17 patients with Eastern Cooperative Oncology Group [ECOG] performance status [PS] 0-1 and 7 patients with PS 2) participated in the trial. Of the 24 refractory patients after CPT-11 containing regimens, 17 patients had been given etoposide plus platinum. There were six partial responses, and an overall response rate of 25% (95% confidence interval, 10-46%) was obtained. The median time to progression and the median survival time after enrollment into this study were 2.8 and 5.8 months, respectively. The median overall survival from the first-line treatment was 19.5 months. The major toxicity was myelosuppression. Grade 4 neutropenia occurred in 13% of patients, and Grade 4 thrombocytopenia was observed in 13% of patients. There was one treatment-related death, attributed to pneumonitis. CONCLUSION: Bi-weekly administrations of ACNU plus paclitaxel provided a practical and well-tolerated regimen that was active for CPT-11-refractory SCLC.
Authors:
Kazutoshi Isobe; Kunihiko Kobayashi; Seiji Kosaihira; Futoshi Kurimoto; Hiroshi Sakai; Yuka Uchida; Yoshiaki Nagai; Takefumi Yamaguchi; Akihiko Miyanaga; Makoto Ando; Gaku Mori; Mitsunori Hino; Akihiko Gemma
Related Documents :
14676118 - Induction chemotherapy followed by concomitant tfhx chemoradiotherapy with reduced dose...
20395128 - First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabi...
7597428 - Paclitaxel in germ cell cancer.
9037368 - A phase i study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovari...
3750178 - Recurrence and survival after anterior resection of the rectum using the end to end ana...
3759538 - Effect of latency on calculated complication rates.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-04-01
Journal Detail:
Title:  Lung cancer (Amsterdam, Netherlands)     Volume:  66     ISSN:  1872-8332     ISO Abbreviation:  Lung Cancer     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-11-09     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8800805     Medline TA:  Lung Cancer     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  350-4     Citation Subset:  IM    
Affiliation:
Department of Respiratory Medicine, Toho University Omori Medical Center, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intelligent analysis in predicting outcome of out-of-hospital cardiac arrest.
Next Document:  Calcite precipitation dominates the electrical signatures of zero valent iron columns under simulate...